BC-CfE Pharmacovigilance 2023 Annual Report
BC-CfE Pharmacovigilance 2023 Annual Report Read More »
Pharmacovigilance Initiative
Antiretroviral Adverse Drug Reaction Report form
To report a suspected adverse drug reaction (“side effect”) to an antiretroviral medication, download and complete the Antiretroviral Adverse Drug Reaction Report form and fax or mail it to the BC-CfE Pharmacovigilance Initiative (address shown on the top of the form). To learn more about HIV drug safety monitoring and adverse drug reaction reporting, click
Antiretroviral Adverse Drug Reaction Report form Read More »
BC-CfE Guidelines for the use of Paxlovid® and ARVs
Safety considerations for nirmatrelvir/ritonavir (Paxlovid¨) use in persons living with HIV whether or not on antiretroviral treatment, or persons at risk of HIV while on PrEP who are diagnosed with COVID-19 infection The COVID-19 therapy Paxlovid¨ consists of the antiviral medication nirmatrelvir co-packaged with the pharmacokinetic enhancer (âboosterâ) ritonavir, taken as a twice daily, oral,
BC-CfE Guidelines for the use of Paxlovid® and ARVs Read More »
BC-CfE research provides real-world data on efficacy of generic cART
First introduced in the mid-1990s through the pioneering work of BC-CfE Executive Director and Physician-in-Chief Dr. Julio Montaner, combination antiretroviral therapy (cART) is a pillar of the Treatment as Prevention¨ strategy that has enabled people living with HIV to live longer and healthier lives and has dramatically reduced the risk of HIV transmission.
BC-CfE research provides real-world data on efficacy of generic cART Read More »
BC-CfE Research Presented at the CAHR 2020 Virtual Conference
The 29th Annual Canadian Conference on HIV/AIDS Research (CAHR 2020) will be going virtual this year. Click Virtual Conference Program in the menu bar for more information. Register now to ensure you receive access to the Conference. Registration is complimentary.
BC-CfE Research Presented at the CAHR 2020 Virtual Conference Read More »